NCT06134401View on ClinicalTrials.gov

Nebulised Hypertonic Saline to Decrease Respiratory Exacerbations in Neuromuscular Disease or Neurodisability

NANot yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Neuromuscular DiseasesNeurodevelopmental DisordersCerebral Palsy
Interventions
DEVICE

saline

nebulised

Trial Locations (2)

SW3 6NP

Royal Brompton Hospital, London

NG7 2UH

Nottingham University Hospitals, Nottingham

Sponsors

Collaborators (1)

Pari Pharma GmbH
All Listed Sponsors
collaborator

Nottingham University Hospitals NHS Trust

OTHER

collaborator

Royal Brompton & Harefield NHS Foundation Trust

OTHER

collaborator

Pari Pharma GmbH

INDUSTRY

lead

Imperial College London

OTHER

NCT06134401 - Nebulised Hypertonic Saline to Decrease Respiratory Exacerbations in Neuromuscular Disease or Neurodisability | Biotech Hunter | Biotech Hunter